[18F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 1, 2015, Pages 56-65

  Beiderwellen, Karsten ^a   Grueneisen, Johannes ^a   Ruhlmann, Verena ^a   Buderath, Paul ^a   Aktas, Bahriye ^a   Heusch, Philipp ^b   Kraff, Oliver ^c   Forsting, Michael ^a   Lauenstein, Thomas C ^a   Umutlu, Lale ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cervical cancer; Ovarian cancer; PET CT; PET MRI

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOBITRIDOL; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RANK SUM TEST; SENSITIVITY ANALYSIS; TUMOR LOCALIZATION; UTERINE CERVIX CANCER; WHOLE BODY IMAGING; CARCINOMA; DIAGNOSTIC USE; EVALUATION STUDY; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; OVARY TUMOR; PATHOLOGY; PELVIS TUMOR; SCINTISCANNING; SECONDARY; UTERINE CERVIX TUMOR;

ADULT; AGED; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; UTERINE CERVICAL NEOPLASMS; WHOLE BODY IMAGING;

EID: 84911877753     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2902-8     Document Type: Article

References (22)

1. Koh W, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Cervical cancer. J Natl Compr Cancer Netw. 2013;11:320–43.
2. Takekuma M, Maeda M, Ozawa T, Yasumi K, Torizuka T. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol. 2005;10:177–81. doi:10.1007/s10147-005-0489-6.
3. Sironi S, Picchio M, Landoni C, Galimberti S, Signorelli M, Bettinardi V, et al. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging. 2007;34:472–9. doi:10.1007/s00259-006-0251-y.
4. Brooks RA, Rader JS, Dehdashti F, Mutch DG, Powell MA, Thaker PH, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009;112:104–9. doi:10.1016/j.ygyno.2008.08.028.
5. Bipat S, Glas AS, van der Velden J, Zwinderman AH, Bossuyt PMM, Stoker J. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol. 2003;91:59–66.
6. Donati OF, Hany TF, Reiner CS, von Schulthess GK, Marincek B, Seifert B, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med. 2010;51:692–9. doi:10.2967/jnumed.109.068510.
7. Ruf J, Lopez Haenninen E, Boehmig M, Koch I, Denecke T, Plotkin M, et al. Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology. 2006;6:512–9. doi:10.1159/000096993.
8. Schreiter NF, Nogami M, Steffen I, Pape U, Hamm B, Brenner W, et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol. 2012;22:458–67. doi:10.1007/s00330-011-2266-4.
9. Tatsumi M, Isohashi K, Onishi H, Hori M, Kim T, Higuchi I, et al. 18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT. Int J Clin Oncol. 2011;16:408–15. doi:10.1007/s10147-011-0202-x.
10. Kitajima K, Suenaga Y, Ueno Y, Kanda T, Maeda T, Deguchi M, et al. Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET/CT and pelvic MRI. Clin Imaging. 2014;38:464–9. doi:10.1016/j.clinimag.2014.02.006.
11. Kitajima K, Suenaga Y, Ueno Y, Kanda T, Maeda T, Makihara N, et al. Value of fusion of PET and MRI in the detection of intra-pelvic recurrence of gynecological tumor: comparison with 18F-FDG contrast-enhanced PET/CT and pelvic MRI. Ann Nucl Med. 2014;28:25–32. doi:10.1007/s12149-013-0777-6.
12. Martinez-Möller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd’hotel C, Ziegler SI, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520–6. doi:10.2967/jnumed.108.054726.
13. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–68. doi:10.1200/JCO.2004.08.120.
14. Keller F, Psychogios G, Linke R, Lell M, Kuwert T, Iro H, et al. Carcinoma of unknown primary in the head and neck: comparison between positron emission tomography (PET) and PET/CT. Head Neck. 2011;33:1569–75. doi:10.1002/hed.21635.
15. Freudenberg LS, Rosenbaum SJ, Beyer T, Bockisch A, Antoch G. PET versus PET/CT dual-modality imaging in evaluation of lung cancer. Radiol Clin North Am. 2007;45:639–44. doi:10.1016/j.rcl.2007.05.003.
16. Scharitzer M, Ba-Ssalamah A, Ringl H, Kolblinger C, Grunberger T, Weber M, et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol. 2013;23:2187–96. doi:10.1007/s00330-013-2824-z.
17. Kim CK, Park BK, Choi JY, Kim B, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr. 2007;31:868–75. doi:10.1097/rct.0b013e31803e8c45.
18. Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, MacKinnon J, Giuliano A. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control. 2009;20:1129–38. doi:10.1007/s10552-009-9317-z.
19. Brix G, Lechel U, Glatting G, Ziegler SI, Munzing W, Muller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608–13.
20. Schwenzer NF, Schraml C, Muller M, Brendle C, Sauter A, Spengler W, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging – pilot study. Radiology. 2012;264:551–8. doi:10.1148/radiol.12111942.
21. Beiderwellen K, Gomez B, Buchbender C, Hartung V, Poeppel TD, Nensa F, et al. Depiction and characterization of liver lesions in whole body (18)F-FDG PET/MRI. Eur J Radiol. 2013;82:e669–75. doi:10.1016/j.ejrad.2013.07.027.
22. Buchbender C, Hartung-Knemeyer V, Beiderwellen K, Heusch P, Kuhl H, Lauenstein TC, et al. Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection? Eur J Radiol. 2013;82:877–82. doi:10.1016/j.ejrad.2013.01.019.